Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma with Alectinib

We report the case of a patient with ALK translocated ALCL with CNS involvement who developed debilitating neuropathy after chemotherapy and was treated with alectinib at relapse. The patient had a complete response after 6 weeks which has continued for 6 months allowing him to undergo an allogeneic stem cell transplant. To our knowledge, this is the first published case report of a patient with ALCL successfully treated with alectinib.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research